Refine by
Tumor Cells Articles & Analysis
268 articles found
One such approach involves the repositioning, or repurposing, of drugs already FDA approved in either non-oncology disease states and/or approved in a limited number of tumor types. The repurposing of these drugs for new indications represents an opportunity to circumvent the time and investment that must go into the discovery, development, and approval of new compounds (1). ...
In the case of human ovarian epithelial cells, SV40 plays a pivotal role. The large T antigen of SV40 has the capability to bind and inactivate tumor suppressor proteins such as p53 and Rb, which are critical regulators of the cell cycle. ...
Tumor cells divide at a much faster rate than normal cells because they show significant dysregulation in cell cycle-related proteins. ...
Cancer Treatment: By delivering genes that can induce cancer cell death or enhance the immune response against tumors, adenoviruses are part of innovative approaches in oncology. ...
Unlike other viral vectors, lentiviruses can transduce both dividing and non-dividing cells, broadening the scope of potential applications. This property is particularly beneficial for targeting tissues that are not actively dividing, such as neurons and certain types of stem cells. ...
By masking lipophilicity, PEG linkers help highly-loaded ADCs reach their target cells with improved pharmacokinetics. l Increased Drug Loading: Hydrophilic PEG linkers enable higher DAR by solubilizing hydrophobic payloads, allowing more drug molecules per antibody. l Improved Pharmacokinetics: The PEG chain prolongs circulation. ...
The BCL2 gene, short for B-cell lymphoma 2, is a critical regulator of apoptosis, or programmed cell death. ...
Active Pharmaceutical Ingredients (APIs) form the foundation of modern pharmaceuticals, serving as the biologically active components responsible for the therapeutic effects of medications. These crucial compounds undergo rigorous research, development, and manufacturing processes before being integrated into final pharmaceutical formulations. The pharmaceutical landscape encompasses a diverse ...
The complex nature of cancer treatment highlights the critical requirement for therapies that show both effectiveness and precise targeting of tumor biology. The conventional treatment approaches fail to accurately target cancer cells, which results in numerous adverse effects while diminishing treatment success. FAP-targeted therapeutics development services ...
Cancer treatment has witnessed transformative advancements over the past few decades, notably with the emergence of CAR-T (Chimeric Antigen Receptor T-cell) therapy. This revolutionary therapy harnesses the body's immune system by genetically engineering T-cells to target and destroy cancer cells. ...
Circulating Tumor Cells, or CTCs, are cancer cells that have shed from the primary tumor and enter the bloodstream, where they can travel and potentially lead to metastasis. These cells are of significant interest in oncology due to their potential to provide vital information about the ...
They work by binding to foreign molecules, known as antigens, which can be proteins, polysaccharides, or other substances found on pathogens or abnormal cells. By binding to these antigens, antibodies can neutralize pathogens directly or mark them for destruction by other immune cells. ...
Glycoprotein 1b on platelet surfaces assists tissue regeneration and injury repair by attaching to von Willebrand factor (vWF) and collagen from damaged blood vessels and when activated P-selectin from platelets becomes externalized it binds to PSGL-1 or CD44 on tumor cells thereby forming a defensive wall against tumor cells. ...
Traditional cancer treatments do not possess the necessary precision to target only cancer cells which leads to poor treatment results and harmful side effects. ...
When administered, the RDCs selectively bind to the cancer cells, allowing for localized delivery of radiation. The development of RDCs involves biochemistry, molecular biology, and radiology. ...
The monoclonal antibody is designed to bind specifically to cancer cells, ensuring that the toxic drug is delivered directly to the tumor, thereby minimizing damage to healthy cells. ...
Hydroxyapatite (HA), a naturally occurring mineral form of calcium apatite, has emerged as a cornerstone material in modern science and technology. Its unique properties, such as biocompatibility, bioactivity, and structural similarity to human bone and teeth, make it indispensable in fields like biomedical engineering, environmental science, and advanced materials. This article delves into the ...
ByMatexcel
For decades, the medical field has seen incredible advances in technology – from new diagnostic capabilities to improved treatments that have saved countless lives. One of these impressive solutions is radiopaque markers – small devices used to diagnose and treat a variety of conditions, ranging from cardiovascular problems to cancer. Not only do they help doctors better understand ...
Watertown, MA – March 24, 2025 – Biopharma PEG, a leading supplier of high-quality polyethylene glycol (PEG) derivatives, highlights its innovative product DSPE-PEG-Mannose, an advanced biomedical polymer with significant potential in drug delivery, tumor-targeted therapy, tissue recognition, and adhesion.Structural Advantages of DSPE-PEG-MannoseDSPE-PEG-Mannose is composed of ...
Anti-Tumor APIs: Pioneering Cancer Treatment Anti-tumor Active Pharmaceutical Ingredients (APIs) are vital in today's medical landscape, addressing one of the most pressing health challenges: cancer. These APIs form the foundation of various therapeutic strategies aimed at inhibiting or destroying tumor cells in the human body. ...